Patient Care

Interim Analysis of KarMMa-3 Trial Finds 51% Reduction in Risk of Progression or Death with Ide-cel in RRMM

05.25.23

Interim Analysis of KarMMa-3 Trial Finds 51% Reduction in Risk of Progression or Death with Ide-cel in RRMM

by Eleanor Mayfield, ELS

IL-18-secreting anti-DLL3 CAR T cells SCLC models

05.23.23

IL-18-secreting anti-DLL3 CAR T cells SCLC models

by ASTCT Science Highlights

TCR-T cells expressing zBBΔBRM shows potent antitumor activity

05.22.23

TCR-T cells expressing zBBΔBRM shows potent antitumor activity

by ASTCT Science Highlights

AI-Assisted Analysis Helps Identify New CAR T Cell Therapy Targets in AML

05.18.23

AI-Assisted Analysis Helps Identify New CAR T Cell Therapy Targets in AML

by Eleanor Mayfield, ELS

EGFRvIII-specific CAR against glioblastoma in preclinical research

05.16.23

EGFRvIII-specific CAR against glioblastoma in preclinical research

by ASTCT Science Highlights

CAR-iNKT Cells Inhibit Growth of T-Cell Lymphomas In Vivo

05.11.23

CAR-iNKT Cells Inhibit Growth of T-Cell Lymphomas In Vivo

by Eleanor Mayfield, ELS

TET2 Disruption Enhances CAR T Cell Efficacy but Elevates Risk of a Hyperproliferative State

05.04.23

TET2 Disruption Enhances CAR T Cell Efficacy but Elevates Risk of a Hyperproliferative State

by Eleanor Mayfield, ELS

Ide-cel vs Standard Therapy in r/r multiple myeloma

05.02.23

Ide-cel vs Standard Therapy in r/r multiple myeloma

by ASTCT Science Highlights

5-year follow-up of Axicabtagene Ciloleucel in LBCL

04.18.23

5-year follow-up of Axicabtagene Ciloleucel in LBCL

by ASTCT Science Highlights

THANK YOU TO OUR SPONSORS

Jansen Oncology

Legend Biotech